BriaCell Therapeutics (BCT) Registration filing summary

Company overview and business model

• Clinical-stage biotechnology company focused on developing novel immunotherapies for cancer, with lead programs in metastatic breast cancer and preclinical assets in prostate cancer and other indications.

• Lead candidate Bria-IMT™ is in a pivotal Phase 3 trial for metastatic breast cancer, with Fast Track Designation from the FDA.

• Pipeline includes Bria-OTS™, a personalized off-the-shelf immunotherapy, and Bria-PROS+™ for prostate cancer, both in early clinical or preclinical stages.

• Recent clinical data show promising efficacy and safety in heavily pretreated breast cancer patients, including those resistant to antibody-drug conjugates and with CNS metastases.

Financial performance and metrics

• For the nine months ended April 30, 2025, reported operating loss of $18.7 million and net loss of $18.2 million.

• Cash and cash equivalents as of April 30, 2025, were $12.5 million; pro forma for the offering, cash would be $30.5 million.

• Share consolidation (1-for-15) effective January 2025 to maintain Nasdaq listing compliance.

• No revenues reported; company is dependent on external financing to fund operations.

Use of proceeds and capital allocation

• Estimated net proceeds of $18.04 million (assuming full subscription) to be used for working capital, general corporate purposes, and advancement of business objectives.

• Management has broad discretion over use of funds; specific allocations not detailed.